Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
Neurocrine Biosciences (Nasdaq: NBIX) announced participation in upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Neurocrine Biosciences (Nasdaq: NBIX) announced participation in upcoming investor conferences. CEO Kevin Gorman will present at the Cowen 42nd Annual Virtual Health Care Conference on March 8, 2022, at 9:10 a.m. ET. He and CFO Matt Abernethy will also present at the Barclays Global Healthcare Conference on March 16, 2022, at 3:50 p.m. ET in Miami. Additionally, Kyle Gano will speak at the 1st Annual Needham Virtual Neuroscience Forum on the same day at 1:50 p.m. ET. Webcasts will be available on the company's website.
Details
News Market Reaction – NBIX
The recorded move for NBIX in the trading session of this news was -0.03%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, March 1, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences:
- Kevin Gorman, Chief Executive Officer, will present at the Cowen 42nd Annual Virtual Health Care Conference at 9:10 a.m. Eastern Time on Tuesday, Mar. 8, 2022.
- Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the Barclays Global Healthcare Conference at 3:50 p.m. Eastern Time on Wednesday, Mar. 16, 2022 in Miami.
- Kyle Gano, Chief Business Development and Strategy Officer, will present at the 1st Annual Needham Virtual Neuroscience Forum at 1:50 p.m. Eastern Time on Wednesday, Mar. 16, 2022.
The live presentations will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentations will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, as well as over a dozen mid-to-late-stage clinical programs in multiple therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-upcoming-healthcare-conferences-301493223.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.